Treatment of Severe COVID-19
For hospitalized patients with severe COVID-19 (SpO2 ≤94% on room air), administer dexamethasone 6 mg daily for up to 10 days combined with remdesivir, and add a JAK inhibitor (baricitinib or tofacitinib) or tocilizumab as a second immunomodulator for patients requiring supplemental oxygen or high-flow oxygen. 1, 2
Core Treatment Algorithm
Step 1: Corticosteroid Therapy (Foundation)
- Dexamethasone 6 mg daily (oral or IV) for up to 10 days or until hospital discharge 1, 3, 4
- This is the single most important intervention that reduces mortality in severe COVID-19
- Do NOT use in patients who don't require oxygen (potential harm) 5
Step 2: Antiviral Therapy
- Remdesivir should be administered in combination with dexamethasone 6, 7
- Most effective when started early in hospitalization
- Continue based on clinical response and viral clearance 8
Step 3: Second Immunomodulator (For Patients on Supplemental/High-Flow Oxygen)
Choose ONE of the following:
Option A: JAK Inhibitors (Preferred for severe disease not on mechanical ventilation)
- Baricitinib OR Tofacitinib 10 mg every 12 hours for up to 14 days 1
- Tofacitinib shows most benefit in patients on supplemental or high-flow oxygen specifically 1
- Critical requirement: Must be on at least prophylactic-dose anticoagulation 1
- Do NOT combine with tocilizumab or other IL-6 inhibitors 1
Option B: IL-6 Inhibitor
- Tocilizumab for patients with severe COVID-19 9, 6
- Particularly useful in patients with evidence of hyperinflammation
- Cannot be used if JAK inhibitor already initiated 1
Step 4: Thromboprophylaxis (Mandatory)
- Enhanced thromboprophylaxis at intermediate or therapeutic doses 3, 10
- Higher than standard prophylactic dosing due to COVID-19-associated coagulopathy
- Especially critical if using JAK inhibitors, which require at least prophylactic anticoagulation 1
- Consider therapeutic dosing if: obesity, known thrombophilia, ICU admission, or elevated D-dimers 3
Oxygen Support Strategy
For Severe Hypoxemia (SpO2 <90% despite oxygen):
- First attempt: High-flow nasal oxygen or non-invasive ventilation 3, 10
- If failing: Proceed to intubation and invasive mechanical ventilation 3, 4
- For ARDS: Implement protective ventilation strategies and prone positioning 10, 4
Critical Exclusions and Contraindications
Do NOT use JAK inhibitors if:
- History of thrombosis or blood clotting disorders 1
- Active cancer 1
- Significant cytopenias 1
- Already receiving tocilizumab 1
- Not on anticoagulation 1
Do NOT routinely use:
- Hydroxychloroquine (no benefit, potential harm) 9, 7
- Ivermectin 9
- Azithromycin (unless bacterial coinfection confirmed) 9
- Colchicine 9
- Interferon β-1a 9
Common Pitfalls to Avoid
Using dexamethasone in non-hypoxemic patients: The RECOVERY trial showed potential harm (increased mortality) in patients not requiring oxygen 5
Combining JAK inhibitors with IL-6 inhibitors: This combination is explicitly contraindicated and increases risk without added benefit 1
Inadequate anticoagulation with JAK inhibitors: Tofacitinib requires at least prophylactic anticoagulation; failure to provide this increases thrombotic risk 1
Standard-dose thromboprophylaxis: COVID-19 requires enhanced dosing due to unique coagulopathy 3, 10
Delaying prone positioning in severe ARDS: This is a key intervention for severely hypoxemic patients on mechanical ventilation 10, 4
Special Considerations for 2025
The most recent IDSA guideline update 2 introduces newer agents (vilobelimab for critical illness, abatacept or infliximab for severe/critical illness), though the core regimen of dexamethasone plus remdesivir with selective addition of JAK inhibitors or tocilizumab remains the standard approach based on the strongest evidence 1, 6.
The key to success is early recognition of severe disease (SpO2 ≤94%), immediate initiation of dexamethasone, and prompt addition of appropriate immunomodulation before progression to mechanical ventilation.